MRK Jun 2024 125.000 call
| Previous close | 2.5800 |
| Open | 3.0800 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 125.00 |
| Expiry date | 2024-06-14 |
| Day's range | 3.0800 - 3.1500 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
Business WireFDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment of Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma
RAHWAY, N.J., May 29, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted for priority review a new supplemental Biologics License Application (sBLA) seeking approval for KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy, for the first-line treatment of patients with unresectable advanced or metastatic malignant pleural mesothelioma. The FDA has set a Prescription Drug User Fee
Business WireMerck to Acquire EyeBio
RAHWAY, N.J. & NEW YORK, May 29, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eyebiotech Limited (EyeBio), a privately held ophthalmology-focused biotechnology company, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire EyeBio.
ReutersMerck nears $1.3 billion cash deal for eye-drug company EyeBio, WSJ reports
Merck has said it's in the market for deals of up to around $15 billion as it plans ways to deal with a loss of revenue from its aging cancer immunotherapy Keytruda.
